The combination of a neutral initiation from an average-accuracy firm, negative EPS revisions, and persistent insider selling suggests the bullish consensus may be overly optimistic. Traders should avoid adding new long positions until insider selling abates or EPS estimates stabilize.
Price Chart
Executive Summary
Oppenheimer initiated coverage on Kestra Medical Technologies (KMTS) at Perform on July 21, 2026, without assigning a price target. The stock currently trades at $24.42, well below the consensus mean target of $30.00, implying roughly 23% upside. Consensus is heavily bullish: 11 of 13 analysts rate it Buy or Strong Buy, with only 2 at Hold. Oppenheimer's neutral initiation is a contrarian call relative to the bullish consensus, but the firm's 52% accuracy on 1,808 calls is average. The 30-day analyst activity shows 1 upgrade and 0 downgrades, though EPS estimates for the current quarter have been revised lower over the past 30 days (from -$0.54 to -$0.625). Insider selling by CFO Webster Brian Daniel has been consistent and significant, with five sales totaling ~$796k over the past two months, including three sales on July 15 alone worth ~$337k. This insider selling diverges from the bullish analyst consensus and warrants caution. The bottom line: Oppenheimer's neutral stance and the persistent insider selling create a cautious counter-narrative to the bullish consensus, suggesting traders should wait for clearer signals before adding to positions.
Impact Score
Consensus & Targets
Consensus is 11 Buy/Strong Buy (85%), 2 Hold (15%), 0 Sell/Strong Sell across 13 analysts. The direction is strongly bullish, with the majority of firms rating KMTS as a Buy.
Current price: $24.42. Consensus mean target: $30.00, median: $30.00, high: $32.00, low: $28.00. Implied upside to mean: 22.8%. Oppenheimer did not provide a price target, so its view sits below the consensus range.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-21 | Oppenheimer | initiate | Perform | — |
| 2026-07-15 | BTIG | maintain | Buy | — |
| 2026-04-09 | Goldman Sachs | maintain | Neutral | $17.00 |
| 2026-04-07 | BTIG | reiterate | Buy | $32.00 |
| 2026-03-25 | BTIG | reiterate | Buy | — |
| 2026-03-18 | BTIG | reiterate | Buy | — |
| 2025-12-15 | Goldman Sachs | maintain | Neutral | $25.00 |
| 2025-12-12 | Wells Fargo | maintain | Overweight | $28.00 |
| 2025-12-12 | Piper Sandler | maintain | Overweight | $30.00 |
| 2025-11-18 | BTIG | initiate | Buy | $32.00 |
30-day analyst activity: 1 upgrade, 0 downgrades. EPS revisions are negative: the current quarter estimate fell from -$0.54 to -$0.625 over 30 days, and the next quarter estimate fell from -$0.545 to -$0.615. Full-year estimates also declined. This negative revision trend diverges from the bullish rating consensus.
Firm Track Record — Oppenheimer
Oppenheimer accuracy: 52% on 1808 calls | avg return: 3.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 3 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Wells Fargo | 33% | 1/3 | -4.8% | below average |
| Goldman Sachs | 0% | 0/3 | -34% | below average |
| Piper Sandler | 0% | 0/2 | -31.9% | below average |
Oppenheimer has a 52% accuracy rate on 1,808 scored calls with an average return of 3.6%. This is average relative to peers. Among firms covering KMTS, Wells Fargo (33% on 3 calls), Goldman Sachs (0% on 3 calls), and Piper Sandler (0% on 2 calls) have worse track records. BTIG (not scored in provided data) has been the most active bull with multiple Buy reiterations.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-0.63 | $-0.63 — $-0.62 | $29.0M | ↑1 ↓0 |
| +1q | $-0.61 | $-0.62 — $-0.61 | $31.4M | ↑1 ↓0 |
| 0y | $-2.31 | $-2.33 — $-2.28 | $137.0M | ↑1 ↓0 |
| +1y | $-2.02 | $-2.06 — $-1.98 | $194.6M | ↑1 ↓0 |
Cross-Platform Signals
Insider trades show persistent selling by CFO Webster Brian Daniel: five sales totaling ~$796k from May 15 to July 15, 2026, with three sales on July 15 alone (~$337k). No insider buys. No congressional trades or institutional changes reported. Short interest data is unavailable. The insider selling diverges from the bullish analyst consensus, creating a cautionary signal.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Insider Cluster | $28.76 | awaiting T+20 | — | $28.76 (+0.00%) |
Oct 20, 2026 6d ago | 144 | $27.31 | awaiting T+20 | — | $28.76 (+5.31%) |
Oct 20, 2026 6d ago | ANALYST-UPGRADE | $28.28 | awaiting T+20 | — | $28.76 (+1.70%) |
Sep 30, 2026 26d ago | 144 | $27.12 | awaiting T+20 | — | $28.76 (+6.07%) |
Sep 14, 2026 6w ago | Press Release | $25.18 $26.97 | ▲ +7.11% | ▲ +4.39% | $28.76 (+14.22%) |
Sep 10, 2026 6w ago | Insider Cluster | $22.85 $26.98 | ▲ +18.07% | ▲ +16.21% | $28.76 (+25.86%) |
Sep 10, 2026 6w ago | Press Release | $23.57 $25.77 | ▲ +9.33% | ▲ +7.21% | $28.76 (+22.02%) |
Aug 31, 2026 8w ago | Press Release | $25.12 $28.29 | ▲ +12.62% | ▲ +12.30% | $28.76 (+14.49%) |
Aug 26, 2026 8w ago | Press Release | $26.57 $25.76 | ▼ −3.05% | ▼ −3.27% | $28.76 (+8.24%) |
Aug 11, 2026 10w ago | Insider Cluster | $28.00 $23.57 | ▲ +15.82% | ▲ +13.92% | $28.76 (−2.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers